Tofacitinib 5mg

Tofacitinib 5mg – Quick Overview

Tofacitinib 5mg is an oral Janus kinase (JAK) inhibitor used to treat moderately to severely active rheumatoid arthritis, active psoriatic arthritis, ulcerative colitis, and certain other inflammatory conditions in adults who haven’t responded adequately to other treatments. It works by blocking specific enzymes involved in the immune inflammatory response. Tofacitinib 5mg carries a significant FDA boxed warning and requires close medical supervision.

Medical Supervision & Regulatory Status

Tofacitinib 5mg is FDA-approved and available only by prescription in the United States. It carries an FDA boxed warning regarding serious infections, increased mortality, malignancy, major adverse cardiovascular events (MACE), and thrombosis, so close medical supervision with pre-treatment screening and ongoing monitoring is required throughout therapy.

Clinical Context

Rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis are chronic inflammatory conditions in which the immune system mistakenly attacks the body’s own tissues, causing joint damage, pain, or intestinal inflammation depending on the condition. Left inadequately controlled, these conditions can lead to progressive joint destruction, disability, or ongoing bowel symptoms and complications.

Targeting the immune signaling pathways that drive this inflammation is a treatment strategy used when conventional therapies, such as methotrexate or TNF blockers, haven’t provided adequate relief, because it can more directly interrupt the inflammatory process at a cellular level.

Tofacitinib fits into therapy as a targeted JAK inhibitor, generally reserved for patients who have had an inadequate response or intolerance to one or more standard therapies such as methotrexate or TNF blockers, given its boxed warning and the availability of other treatment options.

How Tofacitinib 5mg Works

Tofacitinib belongs to the Janus kinase (JAK) inhibitor class of medicines. It works by blocking JAK enzymes (JAK1, JAK2, and JAK3) inside immune cells, which are involved in transmitting signals that drive inflammation.

In simple terms, by interrupting these signaling pathways, tofacitinib reduces the activity of certain immune cells and inflammatory proteins that contribute to joint damage or intestinal inflammation, depending on the condition being treated.

By dampening this specific inflammatory signaling, tofacitinib helps reduce symptoms like joint pain and swelling, or intestinal inflammation, supporting better disease control over time, though it must be balanced against its serious safety risks.

What is Tofacitinib 5mg?

Uses / Indications

Rheumatoid arthritis: Used in adults with moderately to severely active disease who have had an inadequate response or intolerance to methotrexate.
Psoriatic arthritis: Used in adults with active disease who have had an inadequate response or intolerance to one or more TNF blockers.
Ankylosing spondylitis: Used in adults with active disease, per current labeling.
Ulcerative colitis: Used in adults with moderately to severely active disease who have had an inadequate response or intolerance to certain other therapies.
Polyarticular course juvenile idiopathic arthritis (pcJIA): Used in patients 2 years of age and older with active disease.

How to Use / Dosage

Tofacitinib 5mg is generally taken twice daily, with or without food, at consistent times each day, exactly as prescribed. Dosage and duration must be individualized by a physician based on the condition being treated, kidney and liver function, and response to therapy; the extended-release version (XR) is not interchangeable with the immediate-release tablet and any switch should be managed by a healthcare provider. If a dose is missed, take it as soon as remembered unless it is close to the next scheduled dose — do not double up. Do not stop this medication suddenly without consulting your doctor, as this can affect disease control.

Side Effects

Most people tolerate tofacitinib reasonably well, though side effects can occur and should be discussed with a doctor. Common effects may include upper respiratory infections, headache, diarrhea, and nasopharyngitis. Serious effects, though less common, may include serious infections (including tuberculosis), blood clots, changes in cholesterol levels, low blood cell counts, and, rarely, gastrointestinal perforation.

Emergency Warning Signs — Seek immediate medical care if you experience:

• Signs of a serious infection (fever, chills, persistent cough, or unusual fatigue)
• Chest pain, shortness of breath, or sudden weakness (possible heart attack, stroke, or blood clot)
• Swelling, pain, or redness in the leg (possible blood clot)
• Yellowing of the skin or eyes (jaundice)
• Severe abdominal pain (possible gastrointestinal perforation)
• Unusual bruising or bleeding
• New or changing skin growths (possible skin cancer)

Warnings & Precautions

Tofacitinib carries an FDA boxed warning covering serious infections leading to hospitalization or death (including tuberculosis and opportunistic infections), higher all-cause mortality including sudden cardiovascular death, increased risk of malignancy, major adverse cardiovascular events, and thrombosis, particularly noted in patients 50 years and older with at least one cardiovascular risk factor. It is contraindicated in patients with known hypersensitivity to tofacitinib and should not be initiated in patients with an absolute lymphocyte count below 500 cells/mm³, an absolute neutrophil count below 1,000 cells/mm³, or hemoglobin below 9 g/dL. Combining tofacitinib with biologic disease-modifying antirheumatic drugs (DMARDs) or potent immunosuppressants such as azathioprine or cyclosporine is not recommended due to increased infection risk. Drug interactions are significant with strong CYP3A4 inhibitors or inducers, which require dose adjustment. Use during pregnancy should generally be avoided, with patients encouraged to enroll in a pregnancy registry if pregnancy occurs, and breastfeeding should be discussed with a physician. Prior to starting, patients should be evaluated for active and latent tuberculosis, viral hepatitis, and baseline blood counts, with ongoing monitoring for infections and lab abnormalities throughout treatment.

Who Should Not Use This Medication

• People with a known hypersensitivity to tofacitinib
• Individuals with active serious infections, including active tuberculosis
• Patients with an absolute lymphocyte count below 500 cells/mm³, ANC below 1,000 cells/mm³, or hemoglobin below 9 g/dL
• Anyone currently taking biologic DMARDs or potent immunosuppressants in combination without physician guidance
• Patients age 50 and older with cardiovascular risk factors, without careful physician risk-benefit discussion

Storage Instructions

Store Tofacitinib 5mg tablets at room temperature, away from excess heat and moisture. Keep the container tightly closed and protect from direct light. Keep out of reach of children and pets, and dispose of unused or expired medication appropriately rather than in household trash.

Frequently Asked Questions

What is the cost of Tofacitinib 5mg without insurance?

The cost without insurance depends on the seller, brand availability, and pack size, and may also vary by location and available discounts. Manufacturer savings programs may also affect out-of-pocket cost.

How can I order Tofacitinib 5mg online?

A valid prescription is required to order this medication. Typically, you upload a prescription or have your doctor send it directly, then order from a licensed pharmacy for home delivery. Always verify the pharmacy is properly licensed before ordering.

Is Tofacitinib 5mg available over the counter?

No, it is not available over the counter in the United States or most other countries. Regulations may vary by region, but medical supervision is required due to its serious boxed warning.

Does Tofacitinib 5mg require a prescription?

Yes, a prescription is required. This ensures proper pre-treatment screening for infections and other risk factors, along with ongoing monitoring for safety.

How long does it take to work?

Some patients notice symptom improvement within 2 to 4 weeks, though full benefit for conditions like rheumatoid arthritis or ulcerative colitis may take up to 3 months of consistent use to assess.

Can I stop taking this medication suddenly?

Stopping should only be done under medical guidance, as this can affect disease control and your doctor may need to adjust your overall treatment plan. If a serious infection develops, treatment may need to be temporarily interrupted under medical supervision.

Does this medication interact with other drugs?

Yes, it interacts significantly with strong CYP3A4 inhibitors or inducers, biologic DMARDs, and potent immunosuppressants. Always tell your doctor about all medications you take before starting therapy.

Resources

MedlinePlus – Tofacitinib: https://medlineplus.gov/druginfo/meds/a613006.html

FDA – XELJANZ (tofacitinib) Prescribing Information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/208246s027lbl.pdf

FDA Drug Safety Communication – JAK Inhibitor Warnings: https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death

References

FDA – XELJANZ (tofacitinib) Full Prescribing Information, including Boxed Warning: https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/208246s027lbl.pdf

FDA Drug Safety Communication – Warnings for JAK Inhibitors: https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death

MedlinePlus – Tofacitinib: https://medlineplus.gov/druginfo/meds/a613006.html

Medical Disclaimer

This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Consult a qualified specialist or physician before using Tofacitinib.